Morgan Stanley Geo Vax Labs, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.3 - $0.57 $14,447 - $27,449	-48,157 Reduced 95.94%	2,040 $0
Q1 2023 May 15, 2023	SELL	$0.62 - $1.11 $4,390 - $7,859	-7,081 Reduced 12.36%	50,197 $33,000
Q4 2022 Feb 14, 2023	BUY	$0.55 - $0.89 $3,459 - $5,598	6,290 Added 12.34%	57,278 $36,000
Q3 2022 Nov 14, 2022	BUY	$0.4 - $1.72 $19,203 - $82,573	48,008 Added 1611.01%	50,988 $56,000
Q2 2022 Oct 27, 2022	SELL	N/A	-2,000 Reduced 40.16%	2,980 $2,000

Q2 2022 Aug 15, 2022	SELL	N/A	-2,000 Reduced 40.16%	2,980 $2,000
Q1 2022 Oct 27, 2022	BUY	N/A	2,000 Added 67.11%	4,980 $6,000
Q4 2021 Feb 14, 2022	BUY	N/A	3,250 Added 187.86%	4,980 $18,000
Q3 2021 Nov 15, 2021	BUY	N/A	1,730 New	1,730 $7,000

Ticker GOVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,744,000
Market Cap $69.3M
Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhag...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.